{
    "nctId": "NCT04790266",
    "briefTitle": "Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients",
    "officialTitle": "Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients",
    "overallStatus": "RECRUITING",
    "conditions": "Cardiotoxicity",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "CMR T2 mapping",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Written informed consent must be obtained before any assessment is performed\n2. Age \u2265 18 years at visit 1\n3. Performance status ECOG 0-1\n4. \\*Stage I-III histology proven breast cancer\n5. Treated with adjuvant radiotherapy and neo/adjuvant anthracycline and/or trastuzumab-based therapy +/- hormonal therapy\n6. Negative pregnancy test (plasma HCG) for all females of childbearing potential (i.e not permanently sterilised- post hysterectomy or tubal ligation status) In the ancillary study patients with stage 0 (DCIS) histology proven breast cancer will also be included.\n\nExclusion Criteria:\n\n1. Known metastatic spread of any cancer\n2. Known active or recurrent hepatic disorder (cirrhosis, hepatitis), ASAT/ALAT 2xULN\n3. Renal function decrease (eGFR \\< 30 ml/min)\n4. Known coronary artery disease\n5. Angina pectoris\n6. Positive or missing pregnancy test (pre- and perimenopausal women) at enrolment visit\n7. Patients with baseline LVEF \\<53% and GLS \\<15%\n8. Patients with pacemaker",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}